Endothelin (ET) is a recently discovered 21 ... The effects of ET are mediated through interaction with two classes of cell surface receptors. The type A receptor (ET-A) has been associated ...

Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist ...

Preclinical Development Updates F230: F230 is a selective endothelin receptor agonist for the treatment of pulmonary arterial hypertension ("PAH”). In May 2024, Gyre Pharmaceuticals received NMPA ...

Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

Clazosentan – an intravenously-administered endothelin A receptor antagonist – is designed to prevent cerebral vasospasm in aSAH patients, a sudden narrowing of blood vessels that can occur in ...

oral endothelin A receptor antagonist atrasentan, and zigakibart, a subcutaneously administered anti-APRIL antibody. Atrasentan was filed with the FDA earlier this year, while zigakibart is in ...

Locally produced vasodilator substances may counteract the constrictive effects of endothelin-1. [31] NO, which is also produced by stellate cells, is a well-characterized endogenous antagonist to ...

In order to survive, organisms are required to have the capacity to detect and rapidly neutralize harmful environmental challenges. In complex organisms such as mammals, two systems mediate this ...